Macrogenics Inc. | Ownership

Companies that own Macrogenics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
OppenheimerFunds, Inc.
4,109,540
9.73%
160,170
0.05%
06/30/2018
Bellevue Asset Management AG
3,257,325
7.71%
93,762
1.03%
06/30/2018
Fidelity Management & Research Co.
3,041,194
7.2%
-369,841
0.01%
06/30/2018
BlackRock Fund Advisors
2,872,799
6.8%
436,938
0%
06/30/2018
T. Rowe Price Associates, Inc.
2,235,971
5.29%
-23,020
0.01%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,222,426
5.26%
-955,000
3.33%
06/30/2018
The Vanguard Group, Inc.
2,024,914
4.79%
378,655
0%
06/30/2018
SSgA Funds Management, Inc.
1,517,112
3.59%
476,510
0%
06/30/2018
Ecor1 Capital LLC
1,450,606
3.43%
0
3.3%
06/30/2018
Point72 Asset Management LP
1,084,417
2.57%
0
0.12%
06/30/2018

About Macrogenics

View Profile
Address
9740 Medical Center Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.macrogenics.com
Updated 07/08/2019
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E.